<DOC>
	<DOCNO>NCT01711931</DOCNO>
	<brief_summary>The purpose study compare efficacy safety everolimus- biolimus-bluting stent everolimus-eluting bioresorbable vascular scaffold stent . The null hypothesis reject significant difference regard lumen late loss 9 month clinical end point death , myocardial infarction TVR 12 month everolimus-eluting biolimus-eluting stent everolimus-eluting bioresorbable vascular scaffold stent .</brief_summary>
	<brief_title>Comparison Everolimus- Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>elective PCI ability willingness provide write informed consent STelevation myocardial infarction previous 48 hour moderate severe renal failure ( defined creatinine clearance 3060 ml/min &lt; 30ml/min respectively ) know presumed hypersensitivity heparin , antiplatelet drug hypersensitivity contrast dye incontrollable premedication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>bioresorbable vascular scaffold stent</keyword>
	<keyword>everolimus</keyword>
	<keyword>biolimus</keyword>
</DOC>